The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

Article Details

Citation
Copy to clipboard

McKeage MJ

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

Expert Opin Investig Drugs. 2008 Jan;17(1):23-9.

PubMed ID
18095916 [ View in PubMed
]
Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

DrugBank Data that Cites this Article

Drugs